HS
XENE icon

HighVista Strategies’s Xenon Pharmaceuticals XENE Stock Holding History

HighVista Strategies’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Sell
35,318
-13,732
-28% -$762K 0.49% 56
2026
Q1 		$2.85M Buy
+49,050
New +$2.26M 0.79% 42
2025
Q4 		– Sell
-82,190
Closed -$3.3M – 179
2025
Q3 		$3.3M Buy
82,190
+36,570
+80% +$1.29M 0.81% 36
2025
Q2 		$1.43M Sell
45,620
-21,168
-32% -$690K 0.52% 73
2025
Q1 		$2.24M Hold
66,788
– – 0.86% 27
2024
Q4 		$2.62M Sell
66,788
-6,974
-9% -$288K 0.97% 25
2024
Q3 		$2.9M Buy
73,762
+1,047
+1% +$42.2K 1% 31
2024
Q2 		$2.84M Hold
72,715
– – 1.04% 22
2024
Q1 		$3.13M Buy
72,715
+20,914
+40% +$962K 1.12% 25
2023
Q4 		$2.39M Buy
51,801
+16,546
+47% +$585K 0.87% 37
2023
Q3 		$1.2M Buy
35,255
+17,680
+101% +$661K 0.56% 50
2023
Q2 		$677K Sell
17,575
-7,765
-31% -$309K 0.31% 101
2023
Q1 		$907K Hold
25,340
– – 0.74% 39
2022
Q4 		$999K Buy
25,340
+2,768
+12% +$101K 0.59% 45
2022
Q3 		$815K Buy
22,572
+137
+0.6% +$4.93K 0.47% 54
2022
Q2 		$682K Sell
22,435
-5,557
-20% -$168K 0.41% 57
2022
Q1 		$856K Sell
27,992
-34,914
-56% -$1.05M 0.54% 52
2021
Q4 		$1.97M Sell
62,906
-12,140
-16% -$363K 1.56% 13
2021
Q3 		$1.15M Buy
75,046
+34,087
+83% +$592K 0.76% 44
2021
Q2 		$763K Buy
+40,959
New +$755K 0.54% 60
2020
Q4 		– Sell
-43,517
Closed -$482K – 133
2020
Q3 		$482K Buy
43,517
+23,278
+115% +$274K 0.35% 54
2020
Q2 		$254K Buy
+20,239
New +$258K 0.21% 70

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

HighVista Strategies's XENE Position: Q2 2026 in Review

HighVista Strategies reduced its Xenon Pharmaceuticals (XENE) stake by 28% in Q2 2026, selling an estimated $762K and leaving 35,318 shares worth $2.13M. The position accounts for 0.49% of the portfolio, ranked #56.

HighVista Strategies first reported a position in XENE in Q2 2020 and has held it in 22 quarters since. The position peaked at $3.3M in Q3 2025. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • HighVista Strategies held 35,318 shares of Xenon Pharmaceuticals worth $2.13M as of Q2 2026.
  • HighVista Strategies sold 13,732 Xenon Pharmaceuticals shares in Q2 2026, an estimated $762K.
  • Xenon Pharmaceuticals made up 0.49% of HighVista Strategies's portfolio in Q2 2026, its #56 holding.
  • HighVista Strategies first reported a position in Xenon Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • HighVista Strategies's Xenon Pharmaceuticals position peaked at $3.3M in Q3 2025.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.